SCHEMBL494833

SCHEMBL494833

COC(=O)CCCCCCCCCCCCCCCCC(C)C(=O)OC

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 5/20 0.47
ALDH1A1 P00352 1/20 0.47
PABPC1 P11940 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
ZDHHC7 Q9NXF8 1/20 0.42
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.40
PPARG P37231 1/20 0.40
USP2 O75604 1/20 0.39
DGKA P23743 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495887 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL580348 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL494385 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL494409 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL493846 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL495446 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL494822 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL494661 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL579305 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1
SCHEMBL29138959 1.00 TSHR (0.52) TSHRL3MBTL1LMNAALDH1A1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794547-B1 PROCESS FOR THE PREPARATION OF ESTERS FROM FORMATES AND COMPOUNDS OLEFINICALLY UNSATURATED EVONIK DEGUSSA GMBH (DE) 2019-02-06 EP disclosed
CN-103987690-B The method being prepared ester by formic acid esters and alefinically unsaturated compounds 赢创德固赛有限公司 2016-08-24 CN disclosed
US-9340485-B2 Process for preparing esters from formates and olefinically unsaturated compounds EVONIK INDUSTRIES AG (DE) 2016-05-17 US disclosed
EP-2794547-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS Evonik Industries AG (DE) 2014-10-29 EP disclosed
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS EVONIK INDUSTRIES AG (DE) 2014-10-16 US disclosed
WO-2013092478-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS EVONIK INDUSTRIES AG (DE) 2013-06-27 WO disclosed
US-20130072648-A1 SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR PRODUCING OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-21 US disclosed
US-8105970-B2 Olefin polymerization catalyst component and production process thereof, and production proces of olefin polymerization catalyst and olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-31 US disclosed
US-20110245439-A1 OLEFIN POLYMERIZATION CATALYST COMPONENT AND PRODUCTION PROCESS THEREOF, AND PRODUCTION PROCES OF OLEFIN POLYMERIZATION CATALYST AND OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS FDPS, ELOVL6, ELOVL3 TSHR 4694/4885L3MBTL1 3498/4885LMNA 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.